357337-00-9

Basic information

• Product Name: Brivaracetam (alfaR, 4R)-Isomer
• Synonyms: Brivaracetam (alfaR, 4R)-Isomer;2R-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide
• CAS NO: 357337-00-9
• Molecular Formula: C₁₁H₂₀N₂O₂
• Molecular Weight: 212.29
• Mol File: 357337-00-9.mol

Chemical Properties

• Boiling Point: 409.3±28.0 °C(Predicted)
• Appearance: /
• Density: 1.062±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: 15.74±0.50(Predicted)
• CAS DataBase Reference: Brivaracetam (alfaR, 4R)-Isomer(CAS DataBase Reference)
• NIST Chemistry Reference: Brivaracetam (alfaR, 4R)-Isomer(357337-00-9)
• EPA Substance Registry System: Brivaracetam (alfaR, 4R)-Isomer(357337-00-9)

Safety Data

• Hazardous Substances Data: 357337-00-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Brivaracetam (alfaR, 4R)-Isomer is used as a reagent for the preparation of 2-Oxo-1-pyrrolidine derivatives, which are known for their anticonvulsant properties. This application is crucial in the development of new medications to treat epilepsy and other seizure disorders.
Additionally, as an impurity in Brivaracetam (B677645), the alfaR, 4R)-Isomer plays a role in the overall effectiveness and safety profile of the medication. Understanding and controlling the presence of this isomer in the final product is essential for ensuring the therapeutic benefits and minimizing potential side effects for patients with epilepsy.

Upstream product

• 357336-99-3 C₁₁H₂₀N₂O₂ 
• 63095-51-2 (+)-(R)-4-propyl-4,5-dihydrofuran-2(3H)-one 
• 112106-16-8 (R)-2-((tert-butoxycarbonyl)methyl)pentanoic acid 
• 7682-20-4 (R)-2-aminobutanamide hydrochloride 
• 357336-99-3 (2S)-2-(4-propylpyrrolidin-2-one)butanamide 

Downstream Products

• 357336-20-0 brivaracetam 
• 357336-99-3 C₁₁H₂₀N₂O₂ 

Relevant articles and documents

Identification, characterization, synthesis and strategy for minimization of potential impurities observed in the synthesis of brivaracetam

A first systematic impurity profile research concerning nine observed and potential process related impurities of antiepileptic drug brivaracetam is reported. Among which three (impurity G/H/I) have not been discovered or reported before, these nine impurities were monitored by HPLC, and their structures were identified on the basis of MS and NMR spectroscopy. In addition to the formation, synthesis, and characterization, strategies for minimizing these impurities to the levels accepted by ICH are also described in this report.

To 2 - (4 - propyl pyrrolidine -2 - one) - butyramide diastereoisomer splitting method

The invention discloses a 2 - (4 - propyl-pyrrolidine - 2 - one) - butyramide two groups of diastereoisomer splitting method. In particular to (2 S, 4 R) - 2 - (4 - propyl-pyrrolidine - 2 - one) - d amide and (2 S, 4 S) - 2 - (4 - propyl-pyrrolidine - 2 - one) - butyramide splitting, or (2 R, 4 R) - 2 - (4 - propyl-pyrrolidine - 2 - one) - d amide and (2 R, 4 S) - 2 - (4 - propyl-pyrrolidine - 2 - one) - butyramide splitting. The invention provides the use of silica gel as the stationary phase splitting method, in order to mix the organic solvent as eluant, can obtain more separation yield is greater than or equal to 90%, optical purity>de 98% of the target compound.

4-SUBSTITUTED PYRR0LIDIN-2-0NES AND THEIR USE

The present invention relates to optically enriched or substantially optically pure 4-substituted-pyrrolidin-2-ones of formula (III), and their uses for the synthesis of 2-oxo-pyrrolidin-l-yl derivatives.

Process for the preparation of 2-oxo-1-pyrrolidine derivatives

The present invention relates to alternative processes for the preparation of 2-oxo-1-pyrrolidine derivatives of formula (I) Particularly, the present invention relates to alternative processes for the synthesis of levetiracetam, brivaracetam and seletracetam.